Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
OMER filed a patent for "masp-2 inhibitors and methods of use" on Fri, May 31, 2024. The patent was officially published on Thu, October 24, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
